RNS Number : 5660O Renalytix PLC 03 October 2023 Renalytix plc ("Renalytix" or the "Company") Issue of Shares LONDON and SALT LAKE CITY , October 3, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that under the Company's Employee Share Purchase Plan (the "ESPP"), 75,328 new
RNS Number : 4486O Renalytix PLC 03 October 2023 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF MAR. THE PERSON RESPONSIBLE FOR ARRANGING THE RELEASE OF THIS ANNOUNCEMENT ON BEHALF OF RENALYTIX IS JAMES MCCULLOUGH , CEO. Renalytix plc ("Renalytix" or the "Company")
LONDON and SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care,
RNS Number : 9254N Renalytix PLC 28 September 2023 Renalytix plc ("Renalytix" or the "Company") Renalytix Reports Full Year Fiscal 2023 Results LONDON and SALT LAKE CITY , September 28, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics
LONDON and SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its fourth quarter and full year fiscal 2023 financial results on Thursday, September 28, 2023, before market open. The Company will host a corresponding conference call and live
RNS Number : 4406N Renalytix PLC 25 September 2023 Renalytix plc ("Renalytix" or the "Company") Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28 LONDON and SALT LAKE CITY , September 25, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX)
RNS Number : 2884N Renalytix PLC 22 September 2023 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF MAR. THE PERSON RESPONSIBLE FOR ARRANGING THE RELEASE OF THIS ANNOUNCEMENT ON BEHALF OF RENALYTIX IS JAMES MCCULLOUGH , CEO.
Doran Brings Significant Diagnostics Sector Experience to Lead the KidneyIntelX Global Sales Effort LONDON and SALT LAKE CITY, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled
RNS Number : 6395L Renalytix PLC 07 September 2023 Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer Doran Brings Significant Diagnostics Sector Experience to Lead the KidneyIntelX Global Sales Effort LONDON and SALT LAKE CITY - September 07, 2023 - Renalytix plc
RNS Number : 8461J Renalytix PLC 21 August 2023 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF MAR. THE PERSON RESPONSIBLE FOR ARRANGING FOR THE RELEASE OF THIS ANNOUNCEMENT ON BEHALF OF RENALYTIX IS JAMES MCCULLOUGH , CEO.
